Remove 2030 Remove Biosimilars Remove Diabetes
article thumbnail

R&D and tech innovation boosting biopharmaceutical market to 2030

European Pharmaceutical Review

These include innovations in biotechnology, the expansion of biosimilar medicines and increasing investment in research and development. Ultimately, the report stated that the demand is being initiated through an increasing incidence of chronic health conditions, such as cancer, diabetes, cardiovascular conditions and autoimmune disorders.

article thumbnail

Obesity drug tirzepatide approval in China strengthens market position amid GLP-1 agonist competition: GlobalData

Express Pharma

Benemae Pharmaceutical’s benaglutide injection (Feisumei) was the first innovator approved for obesity in July 2023 in China followed by Novo Nordisk’s diabetes therapy semaglutide (Wegovy) in June 2024. The global obesity market faces supply issues, prompting Chinese pharma companies to leverage the situation to develop GLP-1 biosimilars.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biocon signs licensing and supply deal for diabetes drug in Brazil

Pharmaceutical Business Review

This partnership is set to enhance the treatment options available to diabetes patients in Brazil. It develops, manufactures and commercialises complex biotech and biosimilar drug products at its production facility in Nova Lima. million cases by 2030, according to the Diabetes Atlas of the International Diabetes Federation (IDF).

article thumbnail

AMTF report reveals that insulin remains out of reach for T1D patients in LMICs, children facing gross inequities

Express Pharma

Children and young people (CYP) living in low- and middle-income countries (LMICs) face gross inequities when it comes to the diagnosis and treatment of type 1 diabetes (T1D). Without sustainable access to diabetes care, they are unable to manage this chronic condition, leading to severe outcomes that are entirely preventable.

article thumbnail

‘Insulin for muscle’ and the AI platform behind it, with Hanadie Yousef

pharmaphorum

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

2nd Translational Digital Pathology & AI Summit

pharmaphorum

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

After rebuffing Biogen, Sage pairs off with Supernus

pharmaphorum

Skip to main content Monday 16 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)